Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A commonly raised question is whether men with benign prostatic hyperplasia (BPH) are at greater risk for prostate cancer than men who have no sign of BPH. A new, nation-wide study of the male population of Denmark over the past 27 years offers us some insights.
Filed under: Diagnosis, Risk | Tagged: association, benign prostatic hyperplasia, BPH, cancer, Denmark, risk | Leave a Comment »
Until very recently, all available guidelines for the early assessment of risk for prostate cancer clearly recommended the use of a physical examination (a digital rectal exam or DRE) in addition to a prostate-specific antigen (PSA) test.
Filed under: Diagnosis, Risk | Tagged: digital rectal examination, DRE, guideline, PSA, risk | 1 Comment »
“Climacturia” is the involuntary release of urine at the time of orgasm during sexual activity. A new paper by a Swedish research team has expanded our understanding of the prevalence of this problem among men after surgery for localized prostate cancer.
Filed under: Living with Prostate Cancer | Tagged: climacturia, radical prostatectomy, sexual activity | Leave a Comment »
Three new articles in the June 15 issue of Oncology review the current data and the potential of proton beam radiation therapy (PBRT) as a first-line treatment for localized prostate cancer. The full texts of all three articles are available on line.
Filed under: Management, Treatment | Tagged: cost, lozalized, outcome, PBRT, proton beam, radiation therapy | 5 Comments »
A new retrospective analysis of data from > 2,300 patients suggests that African-American men are a greater risk for biochemical disease recurrence after brachytherapy alone than Hispanics or Caucasian men, but
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: African American, brachytherapy, mortality, outcome, race, recurrence | 1 Comment »
The “New” Prostate Cancer InfoLink is delighted to see the early results of a major study conducted by the National Bureau of Economic Research which has effectively proven that patients on Medicaid find regular doctors, see those doctors more often, feel better, are less depressed, and are better able to maintain financial stability than those [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: health care, Medicaid, quality, uninsured | 2 Comments »
According to a media release from Regeneron Pharmaceuticals, the company plans to continue the randomized, multi-center, Phase III VENICE clinical trial, designed to evaluate the efficacy and safety of aflibercept (ZALTRAP™) in combination with docetaxel in the first-line treatment of patients with metastatic, hormone-refractory prostate cancer.
Filed under: Drugs in development | Tagged: aflibercept, hormone refractory, Regeneron, trial | 8 Comments »
An amendment to the Defense Appropriations Act offered by Congressman Cliff Stearns (R, FL) on the floor of the House of Representatives yesterday has added back $16 million to the Department of Defense’s Prostate Cancer Research Program (PCRP). The amendment was passed by a voice vote and supported by members of both political parties.
Filed under: Uncategorized | Tagged: Department of Defense, DoD, PCRP, Prostate Cancer Research Program | Leave a Comment »
Back in 2006 a report from a research team in the Tyrol, Austria, suggested that the availability of free PSA testing for prostate cancer risk had lowered the risk of prostate cancer mortality in the Tyrol as compared to all other areas of Austria. This original study is discussed elsewhere on this web site.
Filed under: Diagnosis, Management, Risk | Tagged: mortality, PSA, screening, testing, Tyrol | 5 Comments »
A previously unanswered question is whether a finding of perineural invasion in the biopsy cores of men who otherwise meet all relevant criteria for management by active surveillance does or does not actually increase risk for progressive forms of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: active surveillance, biopsy, perineural invasion, risk | Leave a Comment »
Here in the USA, while our legally elected representatives in Washington, DC, pontificate about “death panels” and try to score political points over which of our two major political parties is more likely to “ration Grandpa to death,” most of us do, in fact, appreciate that we are going to die (at some point) and [...]
Filed under: Living with Prostate Cancer, Management | Tagged: death, palliative care, quality of life | 7 Comments »
White race and low bone mineral density (osteoporosis) appear to be the only two of a dozen different potential risk factors that significantly increase the likelihood of vertebral (spinal and hip) fractures among men being treated with androgen deprivation therapy (ADT) for prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, fracture, risk, vertebral | 1 Comment »
We are pleased to announce that Prostate Cancer International (the parent non-profit organization that provides the services of this web site) has been rated as one of 122 “Top-Rated Health Nonprofit” organizations based in the USA by Great NonProfits as a consequence of their recent “Health Campaign 2011.”
Filed under: Uncategorized | 3 Comments »
Over the years, data have clearly shown that where a patient has surgical treatment for localized prostate cancer has little impact on short- and long-term outcomes (although who carries out the surgery very definitely does).
Filed under: Management, Treatment | Tagged: Ontario, outcome, positive surgical margin, PSM, radical prostatectomy | 5 Comments »
An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: LHRH agonist, long-acting, recovery, serum, short-acting, testosterone | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site